Ozempic (oral semaglutide) NDC 0169-1709

NDC codes

FDA NDC Directory

Product NDC (as listed)0169-1709Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00169-1709Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0169-1709-30	00169170930	30 TABLET in 1 BOTTLE, PLASTIC (0169-1709-30)Marketed from Apr 27, 2026

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ozempic
Generic name (nonproprietary): oral semaglutide
Active ingredients: Semaglutide — 9 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Novo Nordisk Pharmaceutical Industries, LP
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 213051
Marketing start: Apr 27, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Glucagon-Like Peptide 1 (Chemical structure)Glucagon-like Peptide-1 (GLP-1) Agonists (Mechanism)
Identifiers: Product ID 0169-1709_6834044a-22f1-4f35-b846-b3448ee84c16SPL ID 6834044a-22f1-4f35-b846-b3448ee84c16SPL set ID 27f15fac-7d98-4114-a2ec-92494a91da98RxCUI 2200644, 2200650, 2200652, 2200654, 2200656, 2200658, 2707547, 2707549, 2707551, 2707553, 2707555, 2707557, 2736944, 2736946, 2736948UNII 53AXN4NNHX
Pharmacologic class: GLP-1 Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400169170930 followed by a unit qualifier and the quantity

Package 00169-1709-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 30, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 (GLP-1) receptor agonists indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke)…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 213051

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 213051
Product	Strength	Form · route	Labeler	Product NDC
Ozempicoral semaglutide	Semaglutide 4 mg/1	TabletOral	Novo Nordisk Pharmaceutical Industries, LP	0169-1704
Ozempicoral semaglutide	Semaglutide 1.5 mg/1	TabletOral	Novo Nordisk Pharmaceutical Industries, LP	0169-1715
Rybelsusoral semaglutide	Semaglutide 3 mg/1	TabletOral	Novo Nordisk Pharmaceutical Industries, LP	0169-4303
Rybelsusoral semaglutide	Semaglutide 7 mg/1	TabletOral	Novo Nordisk Pharmaceutical Industries, LP	0169-4307
Rybelsusoral semaglutide	Semaglutide 14 mg/1	TabletOral	Novo Nordisk Pharmaceutical Industries, LP	0169-4314